RxDoctor Payments Data

Morgan Leak, MD

Internal Medicine · Amarillo, TXNPI 1700048006

Payments from drug & device makers

$772in general payments, 2019–2025

Across 71 payments — averaging $10.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$325
  • AstraZeneca$207
  • Insulet Corporation$48
  • Novo Nordisk$29
  • Johnson & Johnson$27
  • Medtronic$27
  • plus $109 from 7 others

What the payments were for

  • Food & beverage$772100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$772 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$11,992
Medicare patients
245
Services billed
850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin204$263,440
Trelegy ElliptaFluticasone/Umeclidin/Vilanter173$210,823
OzempicSemaglutide122$206,492
RybelsusSemaglutide52$98,841
FarxigaDapagliflozin Propanediol64$60,145
ZenpepLipase/Protease/Amylase11$59,218
EliquisApixaban44$57,606
Tresiba Flextouch U-100Insulin Degludec50$51,040
Tresiba Flextouch U-200Insulin Degludec30$44,673
LinzessLinaclotide23$23,228
MounjaroTirzepatide18$22,404
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$16,821
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$14,271
Breo ElliptaFluticasone/Vilanterol12$10,264
NovologInsulin Aspart22$8,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$29$313,858196 claims
GSKTrelegy Ellipta, Breo Ellipta$325$221,087185 claims
AstraZenecaFarxiga, Breztri Aerosphere$207$76,96676 claims
PfizerEliquis$12$57,60644 claims
Sanofi-aventis U.S. LLCLantus$23$5,87723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →